Long-Term Safety of Tedizolid in a Patient With Spondilodiscitis After Switch From Linezolid Due to Toxicity

The patient is a 57-year-old man with liver cirrhosis, Bricker anastomosis after a radical cystoprostatectomy and, a history of bacteremias caused by extended-spectrum β-lactamase–positive Escherichia coli, Enterococcus faecium, and Candida albicans. He presented with persistent low back pain and was diagnosed with vertebral osteomyelitis, for which he received ertapenem-linezolid treatment. However, after 20 days, linezolid had to be discontinued because of myelotoxicity and metabolic acidosis. The patient was switched to tedizolid, which, in combination with ertapenem, was successfully given for 114 days until biopsy showed no growth of gram-positive cocci. We conclude that tedizolid can be an alternative to linezolid in case of toxicity, especially in long-term treatments. Correspondence to: Rosa Maria Martínez Álvarez, MD, PhD, Infectious Diseases Unit, Antimicrobial Stewardship, Internal Medicine Department, Miguel Servet University Hospital, Avenida Isabel La Católica 1-3, 50009 Zaragoza, Spain. E-mail: rmartineza@salud.aragon.es. The authors have no conflicts of interest to disclose. Editorial assistance was provided by Content Ed Net, Madrid, Spain. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

http://ift.tt/2FbTPmO